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Compartmental distribution of complement activation products in
artificial kidneys. The compartmental distribution of the human
anaphylatoxins C3a and C5a has been defined during simulated
hemodialysis performed with various types of hemodialyzers. New
cuprophan hollow fiber dialyzers were found to activate human com-
plement very readily in vitro, while re-used cuprophan dialyzers
displayed only modest complement activating potential. The C3a and
C5a antigens, formed as a result of complement activation in these
dialyzers, accumulated predominantly in the blood path and were not
adsorbed extensively on the membrane surface or transported into the
dialysate compartment. Cellulose acetate membranes also produced
complement activation in vitro, but to a lesser degree than new
cuprophan hollow fibers. However, these membranes exhibited a
significant capacity to bind the anaphylatoxins to their surface.
Polyacrylonitrile membranes appeared to be unique in that they not
only failed to activate complement significantly, but they rapidly
adsorbed large quantities of C3a and C5a. These findings demonstrate
that hemodialysis membranes may differ with regard to their comple-
ment activating potential as well as their ability to remove circulating
anaphylatoxins from the blood path. Clinical measurements of
anaphylatoxin production during hemodialysis reflect these dynamic
events.
Complement activation, which results in the formation of the
human anaphylatoxins C3a and C5a, is known to occur during
hemodialysis performed with certain types of artificial kidney
membranes [1—4]. Available data strongly suggest the
anaphylatoxins to be the etiologic factors in dialysis leukopenia
[1—3, 5—7]. They have also been proposed to cause some of the
dialysis—related complications such as hypoxemia and the
first—use syndrome [6—91. Prior clinical investigations have
further suggested that dialyzers composed of new cuprophan
hollow fibers tend to activate complement much more readily
than either re-used cuprophan dialyzers [2] or plate dialyzers
composed of polyacrylonitrile [1]. Cellulose acetate hollow
fiber dialyzers appear to display an intermediate ability to
activate complement [3].
These conclusions were based on studies performed by
quantitatively measuring the plasma levels of C3a and C5a
antigens found in the blood of patients during maintenance
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hemodialysis performed with each type of dialyzer. Hypothet-
ically, under these conditions the measured plasma level of
either C3a or C5a might be governed by several different factors
including: 1) their rate of production at the membrane surface;
2) their transport into the dialysate compartment; 3) their
adsorption on the membrane itself; 4) the rate of catabolism in
the patient's body; and 5) in the case of C5a, the rate and extent
of binding of this bioactive molecule to specific receptors found
on the granulocytes of peripheral blood [101. To test the first
three of these hypotheses and further define the properties of
hemodialyzers, we have conducted a series of investigations
that were aimed at defining the rate of transport and sorption of
the anaphylatoxins during simulated hemodialysis performed
with several different commonly—employed hemodialyzers.
Methods
Artificial kidney membranes
Three different commercially available artificial kidney mem-
branes were used in this study. They were cuprophan hollow
fiber (CF-l511, Travenol Laboratories, Inc., Deerfield, illinois,
USA, surface area 0.8 M2), cellulose acetate sheet
(Hemofresh, Daicel Chemical industry, Ltd, Himeji, Japan,
surface area 0.7 M2), and polyacrylonitrile sheet (I2lOH,
Hospal, East Brunswick, New Jersey, USA, surface area = 1.0
M2). The cellulose acetate membrane (Hemofresh) is normally
used for hemofiltration purposes. However, there are two ports
in the ultrafiltrate compartment such that dialysate can enter
and exit as in a hemodialyzer. The polyacrylonitrile membrane
(1210H) can be used for either hemodialysis or hemofiltration
purpose.
The re-used cuprophan membrane hemodialyzers utilized in
this study (CF-151 1) were obtained after routine patient use. All
patients had been on chronic hemodialysis for at least six
months and were free of intercurrent acute illness. None was
taking either corticosteroid or nonsteroidal antiinflammatory
agents. After a single use by the patient, the cuprophan dialyz-
ers were rinsed with water and stored in 2% formalin.
Prior to use in these experiments, the blood path of the
dialyzers was rinsed with one liter of sterile normal saline and
then rinsed with air to remove as much saline as possible.
Effluents from the re-used cuprophan dialyzers were tested with
Schiff's reagent to insure that residual formalin was less than 10
ppm as accepted in clinical practice.
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Preparation of pooled human serum
Whole blood was collected from normal human volunteers in
plastic collection bags containing citrate (CDPA-l). The plasma
obtained by centrifugation was pooled, recalcified with 2 M
calcium chloride, and allowed to clot at 37°C. Serum was then
expressed from the fibrin clots and stored in 250 nil aliquots at
— 70°C.
Preparation of radioiodinated polypep rides
Human C3adesArg and CSadesArg were purified to homogeneity
from zymosan—activated human serum as previously described
[Ill. Equine cytochrome C was purchased from Sigma Chem-
icals (St. Louis, Missouri, USA). These polypeptides (10 ,ag)
were radioiodinated with 1 mCi of either carrier—free Na'25l or
Na1311 (Amersham, Arlington Heights, Illinois, USA) by a
solid—phase lactoperoxidase—glucose oxidase (Enzymobeads)
method as described by the manufacturer (BioRad, Richmond,
California, USA). Free radioisotope was separated from
protein—bound by gel filtration chromatography. The specific
activity of each preparation was determined to he: 1251
C3adesArg, 80 .tCi/g; 1251-C5adesArg, 30 tCi/g; and ''l-
cytochrome C, 20 Ci/ig. In each case, the radiolahelled
polypeptide contained < 5% free iodine as defined by the
precipitability of the protein—bound radioisotope in the pres-
ence of 10% trichloroacetic acid.
Simulated hemodialysis circuits
Simulated hemodialysis was performed in the following man-
ner. A 250 ml aliquot of pooled human serum was placed in a
sterile beaker, warmed to 37°C and pumped through a test
dialyzer at a flow rate of 100 ml/min. Venous outflow from the
dialyzer was returned to the stirred serum pool in the beaker,
thus permitting measurement of the anaphylatoxin antigens as
they accumulated during the period of experimentation. Simul-
taneously, 250 ml of dialysate (Eri-lyte, Erika Inc., Kockleigh,
New Jersey, USA) was warmed to 37°C and recirculated
through the dialysate compartment of the dialyzer in a counter
current direction at a flow rate of 100 mI/mm. Again, the
dialysate compartment loop was a closed system, thus permit-
ting measurement of transported molecules which accumulated
outside the blood path of the dialyzer. Ultrafiltration through
the membrane was minimized by minute—to—minute monitoring
of the compartment volumes and adjustment of the ultrafiltra-
tion pressure throughout the experiment.
Complement activation and anaphylatoxin formation taking
place within the dialyzer was evaluated by removing serum
from the recirculated pooi and mixing it with one—twentieth
volume of 0.2 M disodium ethylenediamine tetraacetic acid
(EDTA) to terminate complement activation. These samples
were then assayed by radioimmunoassay (Upjohn, Kalamazoo,
Michigan, USA) techniques to quantitate the serum levels of
C3a antigen. Control experiments were performed by
recirculating serum through an identical circuit consisting of
polyvinylchloride tubings, but without the presence of a
dialyzer. All serum samples were obtained in duplicate.
Experiments designed to define the fate of radiolahelled
polypeptides were conducted in a similar manner. However,
EDTA (final concentration, 10mM) was added to the pooled
serum prior to recirculation to prevent complement activation
during the course of these investigations. Immediately prior to
recirculation of the serum, I to 2 jCi of radiolahelled peptide
1251-C3adesArg, '251-C5adesArg or '31l-cytochrome was added to
the 250 ml of EDTA-serum and then the study was initiated as
described above. After varied intervals of time. I ml aliquots
were removed from both the serum pool (blood path) and
dialysate compartments. These samples were then counted in a
gamma counter.
cac:ulations
The mass of the tracer substance in either the blood or
dialysate compartment at any given time point was given by the
product of the concentration and measured volume of the fluid
in that compartment. This mass was corrected for the cumula-
tive amount of tracer removed by sampling from that compart-
ment at that time point. The corrected mass was then expressed
as a percentage of total mass added to the serum at the
beginning of the experiment. Mass not detected in either the
serum or dialysate was assumed to he adsorbed onto the
artificial kidney membrane surface. At any given time point,
these relationships are expressed as follows:
% M, = [1 — (M + Md)/CTI X 100
where % M1 Mass adsorbed onto the membrane expressed
as a percentage of the total mass in the system
(C1).
M, Mass corrected for sampling loss in the serum.
M, = Mass corrected for sampling loss in the dialy-
sate compartment.
Differences in concentration at different time points were tested
by Student's paired t statistics. A P value < 0.05 was consid-
ered as statistically significant.
Results
Complement activation during sitnulated heinodialysis
The concentration of C3a antigen found in the recalcified
pooled human serum employed in these studies was 1773 94
(sEM) ng/ml. This value is significantly greater than that of
normal human plasma (76 15 ng/ml) [1], and is thought to
result from complement activation that occurs during the
recalcification and clotting processes [121. However, the func-
tional integrity of the serum complement system was demon-
strated by incubation of this recalcified serum with zymosan for
30 mm at 37°C, which resulted in significant generation of C3a
(final concentration, 35.8 0.9 tg/ml). Therefore, pooled
human serum prepared in this manner may be utilized to
evaluate the complement—activating potential of hemodialyzers
or other artificial medical devices.
Recirculation of the serum through the polyvinylchloride
tubing alone without a dialyzer in the in vitro circuit did not
result in changes of C3a antigen concentration.
The changes in the serum concentration of C3a antigen that
were produced during recirculation of this pooled serum
through different dialyzers is shown in Figure 1. New
cuprophan hollow fiber dialyzers promoted a steady generation
of C3a in the blood compartment throughout the duration of the
experiment, reaching a value of 6541 259 (sEM) ng/ml above
baseline at 90 mm of recirculation. However, even after this
period, steady—state levels of C3a antigen were not achieved,
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Fig. 1. Changes in serum 3a antigen concentration produced by in
vitro recirculation of serum through different hemodialyzers. Hollow
fiber dialyzers composed of new cuprophan (.), cellulose acetate (.)
and re-used cuprophan (0) produce increased concentrations of
C3adcArg. By contrast, use of polyacrylonitrile plate dialyzers (A) is
associated with a decrease in C3a antigen concentration. Data points
represent the mean SEM of duplicate determinations in three separate
experiments. *Denotes values different (P < 0.05) from the correspond-
ing values generated by new cuprophan.
suggesting that neither the membrane's activating capacity nor
the serum pool's complement had been exhausted.
The generation of C3a antigen produced by either re-used
cuprophan or cellulose acetate membranes was measurable, but
relatively modest when compared to that produced by new
cuprophan hollow fibers. Additionally, after 30 mm of recircula-
tion, steady—state concentrations of C3a were achieved with
both of these types of dialyzers.
By contrast, the results obtained with the polyacrylonitrile
membrane were significantly different from the others studied.
When plate dialyzers equipped with this membrane were em-
ployed, serum levels of C3a antigen showed an actual decline
from baseline levels rather than an increase. A significant
diminution in C3a levels was observed as early as 15 mm and
persisted until the end of the recirculation experiment. A
polyacrylonitrile membrane in hollow—fiber format supplied by
another manufacturer (PAN15, Asahi, Tokyo, Japan), as well
as polysulfone (D30, Amicon, Danvers, Massachusetts, USA)
and polycarbonated (20218, Gambro, Lund, Sweden) mem-
branes also promoted a decrement in serum C3adeSArg concen-
tration (data not shown).
Distribution of radio/abel/ed polypeptides during simulated
heinodialysis
The compartmental distribution of the complement fragments
in different types of dialyzers was defined with 251-C3adesArg
and '251-C5adesArg employed as tracers. Additionally, 1311
cytochrome C, which is similar in charge and molecular wt to
both C3a and C5a, was employed as a control tracer molecule to
determine if the observed phenomena were of a general or
specific nature.
The time—dependent distribution of these isotopically—labeled
polypeptides in new cuprophan dialyzers is shown in Figure 2.
These studies demonstrate that distribution and equilibration of
all three polypeptides took place during the first 30 mm of the
experiment. At equilibrium, approximately 80% of C3a, C5a, or
cytochrome C remained in the blood compartment. Transport
of these low molecular wt polypeptides into the dialysate
compartment was negligible (approximately 5% of total) and
about 10 to 20% of the tracers appeared to be bound to the
membrane surface after 90 mm of recirculation. The
time—dependent distribution of each of these polypeptides in
re-used cuprophan dialyzers (Fig. 3) was similar to that ob-
served with new dialyzers.
Both cellulose acetate (Fig. 4) and polyacrylonitrile (Fig. 5)
membranes behaved very differently from cuprophan hollow
fibers. With both of these types of membranes, there was a
greater time—dependent disappearance of '251-C3a, 1251-CSa,
and 1311-cytochrome C from the blood compartment and corre-
sponding accumulation of the tracers on the membrane itself.
Polyacrylonitrile membranes in particular exhibited a pro-
nounced tendency to bind these molecules very rapidly, with
equilibrium being reached within 15 mm after the onset of
recirculation. At equilibrium, polyacrylonitrile membranes
bound > 90% of the available C3a and > 80% of the C5a. By
contrast, only about 40% of the cytochrome C tracer was
adsorbed on these membranes. Transport of these marker
polypeptides into the dialysate compartment by either cellulose
acetate or polyacrylonitrile membranes was low and compara-
ble to that observed with cuprophan membranes.
Discussion
Activation of the complement cascade occurs during clinical
hemodialysis with cuprophan membranes, probably via the
alternative pathway [1, 5]. We have suggested that this process
is initiated with the attachment of metastable C3b onto the
cuprophan membrane surface and subsequent formation of a
surface—bound C3 convertase [1]. The C3 convertase then
converts C3 to C3b, releasing the cationic fragment C3a into the
circulation. Addition of another C3b onto the C3 convertase
complex forms a CS convertase which is capable of converting
C5 to C5b and the cationic glycopolypeptide C5a [131. Once C3a
and C5a arc released into the circulation, they are rapidly
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Fig. 2. Irne—dependent distribution Of'25I-C3Ua,,Ag (A), '21C5O,1,Ag
(B), and '311—cytochrome C (C) in the blood path (0), dialysate co,npart—
merit (4), or adsorbed onto the membrane surface (A) when EDTA-
serum containing tracers is recirculated through new cuprophan hollow
fiber dialvzers.
stable desArg derivatives. The antisera in the currently avail-
able radioimmunoassay (RIA) recognize both the anaphyla-
toxins and their desArg derivatives [121,
Such antigens detectable by RIA arc readily found in the
venous plasma of patients undergoing cuprophan hemodialysis
[lJ. Peak venous plasma concentration of C3a antigen usually
occurs at 15 mm after the onset of treatment achieving values
over 15—fold from baseline, and begin to decline thereafter. It
has further been shown that different types of dialysis mem-
branes are associated with drastically different plasma concen-
trations of the anaphylatoxin antigens [1—31. However, the
dynamic events occurring in the dialyzer as they might affect
























Fig. 3. Time—dependent distribution Of'25JC3U,j,,A,g (A), '251-C5aa,,nrg
(B), and '311-cytochroine C (C), in the blood path (0), dialysate
compartment (.), or adsorbed onto the membrane surface (A) when
EDTA-serum containing tracers is recirculated through re-used
cuprophan hollow fiber dialyzers.
The in vitro system described herein was designed to assess,
in a controlled manner, the bioconipatibility of artificial kidney
membranes from the standpoint of anaphylatoxins. It has
certain clear advantages over measurements taken from pa-
tient's blood during hemodialysis. First, patient variability in
generation and catabolism of the complement fragments can be
eliminated using test serum from a single batch. This makes for
improved ability to discriminate between different membranes.
Secondly, using serum as the test solution avoids largely the
confounding effect of anaphylatoxin adsorption by the cellular
elements in the blood. Thirdly, this system allows assessment
of the compartmental distribution, that is, loss into the dialysate
and onto the membrane, of complement activation products in
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Fig. 4. Time—dependent distribution of'I-3a,,,.5 (A), '251-c5aa,,n(B), and '311-cytochrome C (C) in the blood path. (a), dialysate compart- Fig. 5. Time—dependent distribution of'251-c3ad))Ara (A), '251-C'5aae,Arg(B), and '311-cytochrome C (C) in the blood path (0), dialysate compart-
ment (•), or adsorbed onto the membrane surface (A) when EDTA- ment (.), or adsorbed onto the membrane surface (A) when EDTA-
serum containing tracers is recirculated through cellulose acetate serum containing tracers is recirculated through polyaciylonitrile plate
hollow fiber dialyzers. dialyzers.
the artificial kidneys, as it might affect the final serum concen- but the difference in the number of sites limits the total amount
tration. of C3adesArg which can be eventually generated. This similarity
We found that new cuprophan membranes indeed generate between new cuprophan and cellulose acetate has been ob-
C3aCICSArg vigorously in this in vitro system in a manner analo- served in vivo. Clinical data on the cellulose acetate
gous to the apparent in vivo circumstance, with serum concen- hemofiltration membrane used in the present study have not
tration exceeding 6000 ng/ml above baseline after 90 mm of been reported in the literature. Measurement of plasma
recirculation. Under the identical circumstances, re-used C3adesArg concentration in two of our patients showed values of
cuprophan and cellulose acetate membranes produced signifi- 1170 ng/ml and 769 ng/ml at 15 mm, which were again signifi-
cantly lower concentration of C3adesArg than new cuprophan cantly lower than those seen with new cuprophan membranes.
membranes at the end of recirculation. However, during the Attenuation of complement activating potentials by the re-
initial 30 mm the rate of rise of all three types of membranes was use of cuprophan membrane in the present study agrees with
not significantly different. Presumably, the reactivities of avail- that seen in the patients [21. It is thought to be not due to the
able C3b binding sites on these membranes are rather similar, formalin per se, since new cuprophan membranes treated with
Comparirnentalizarion of complement products 79
formalin alone still activated complement vigorously. The lower
level of activation by re-used cuprophan membrane is thought
to be due to a coating of the membrane surface with C3b-like
molecules, preventing further deposition of active C3b and
formation of C3 convertase.
In contrast to these membranes, recirculation of serum
through polyacrylonitrile membrane in vitro produced a decre-
ment in serum C3adesArg concentration which was evident in the
first 15 mm. This was different from that observed in dialysis
patients where plasma C3adeSArg concentration increased rather
than decreased with the same membrane, although the magni-
tude of increment was only about 10% of that for new
cuprophan membranes I!]. This discrepancy warrants explana-
tion. The decrease seen with polyacrylonitrile in vitro suggested
that rate of removal from the serum was faster than the rate of
formation. There is no reason to suspect that the rate of
removal was faster in vitro than during clinical hemodialysis.
The difference was more likely to be due to the slower rate of
formation in the present study because of the slower serum
flow. Differences in the concentration of substances regulatory
for complement activation such as factor H, I and properdin
were not assessed in the present study. Our preliminary data,
however, suggest that complement activation occurs somewhat
slower in recalcified serum than fresh serum.
The distribution of the C3adesAi.g and CSadesArg molecules in
the artificial kidney membrane system were shown with the
tracer experiments in which continuous complement activation
was prevented by the divalent ion chelator, EDTA. Transfer of
C3adeSArg and CSaIeSAFg into the dialysate compartment, as seen
in the tracer experiments, was not prominent with any of the
membranes, since these polypeptides carry a cationic charge
and molecular wt around 10,000 daltons. The modest membrane
adsorption together with the large capacity to activate comple-
ment probably account for the high concentration of C3adesAig
seen with new cuprophan in clinical dialysis and the present in
vitro study. In contrast, polyacrylonitrile membranes adsorbed
significantly more C3adesArg molecules which contribute to the
fall of C3adesArr concentration in Figure 1. The adsorption of
C3adesAi-g by polyacrylonitrile membrane, however, seemed to
be saturable and was estimated to be 450 g, approximating
only 20% and 2% of the estimated total amount present in the
plasma at the time of peak concentration in patients dialyzed
with polyacrylonitrile and new cuprophan membrane, respec-
tively [1]. Therefore, the activation potential, rather than the
adsorption capacity, seems to be the major determining factor
of the net plasma concentration of C3adesArg in the dialyzed
patients.
Re-used cuprophan membranes were associated with serum
C3adesArg concentration similar to that of cellulose acetate, but
the amount adsorbed was far less, being similar to that of new
cuprophan. In other words, re-use attenuated the complement
activating potential of cuprophan membranes but did not
change the adsorption capacity. The two phenomena are not
associated.
The specificity of CSadeArg and C3adesArg binding to these
membranes were assessed by comparison with cytochrome C, a
molecule with similar molecular wt and isoelectric point. Al-
though not closely correlated, cellulose acetate and poly-
acrylonitrile membranes adsorbed C3adesArg, CSa(,esArr and
cytochrome C more than new or re-used cuprophan. This
suggested that the nature of binding between the complement
fragments and the artificial kidney membranes was rather
nonspecific. It is tempting to postulate that the large propensity
of polyacrylonitrile membranes to adsorb cationic proteins is
related to the anionic nature of its surface. However, there are
two lines of evidence against this hypothesis. First, the
polyacrylonitrile membrane with a neutral surface charge
(PAN 15, Asahi) also promoted a decrement in serum C3adesArg
concentration when tested in vitro (unpublished observation).
Secondly, it has been shown recently that even immunoglobulin
G (isoelectric point = 7.3) and fibrinogen (isoelectric point
5.4) are adsorbed significantly by the anionic polyacrylonitrile
membrane (Hospal) l4]. It seems, therefore, that polyacryloni-
trile membrane has a propensity to adsorb a large variety of
plasma proteins nonspecifically.
Measurements on the serum C3a antigen concentrations in
the present study are in general agreement with those obtained
during clinical hemodialysis [1—4]. The highest concentration is
associated with new cuprophan and the lowest with poly-
acrylonitrile, with re-used cuprophan and cellulose acetate in
between. However, generation rate by an artificial membrane
cannot be determined by plasma concentration alone. Removal
by the patient, membrane and dialysate are all factors which
need to be considered, as indicated above, For example,
although loss of anaphylatoxins into the dialysate compartment
through hemodialysis membranes is small in general, the loss
through a plasmapheresis membrane could be substantial,
Hemodialysis leukopenia is most likely caused by the forma-
tion of the anaphylatoxins. Although not universally agreed
upon, some clinical and animal studies also suggest that com-
plement activation is important in the pathogenesis of certain
dialysis—related complications, such as hypoxemia, pulmonary
hypertension and the first—use syndrome [3, 4, 6—9]. How these
variabilities of artificial membranes in adsorbing and removing
RIA-detectable anaphylatoxin antigens affect the welfare of the
dialysis patients is unknown at present.
In conclusion, artificial kidney membranes possess different
potentials to activate the complement system. Such activation
potentials can be tested conveniently in vitro as described.
Besides generation of the complement activation products,
artificial kidney membranes also adsorb these molecules onto
their surfaces. The capacities of adsorption also differ among
membranes. These two phenomena are not necessarily related.
Membranes which produce the least amount of anaphylatoxins
and simultaneously adsorb the most may be considered as most
biocompatible from the standpoint of complement activation.
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